SANTA CRUZ DE TENERIFE, Dec. 29 (EUROPA PRESS) –
The Governing Council authorized in its session this Thursday the Ministry of Health to make the expense corresponding to the extension of the framework agreements for contracting the supply of medicines for human use type II (exclusive) destined for the Canary Islands Health Service .
The expense amounts to an amount of 334,863,280.74 euros (with IGIC type 0), intended to meet the care needs of the hospital network, Specialized Care Centers (CAE) and Primary Care centers.
Exclusive medicines are those that have no competition because the patent of the laboratories that supply them has not yet expired.
Among them are, for example, innovative cancer medicines, some antiretrovirals, or those indicated for melanoma, multiple sclerosis, breast cancer, atopic dermatitis or asthma, among others, reports the Government in a note.
The supporting report indicates that the corresponding framework agreements with the winning companies were formalized on February 19, 2021, with a validity of two years, extendable for another period of two years, by mutual agreement of the parties.
Given the proximity of the expiration date of the framework agreements and the need to continue with the supply of medicines, it is considered necessary to extend the agreements until February 21, 2025.
For this, there is the corresponding favorable report from the Service for the Rational Use of Medicines and Control of Provision of the General Directorate of Assistance Programs of the Canary Islands Health Service.
